Every value below carries the sentence it was read from.
37 sources stand behind the page.
Field
Value
Cited text
Known as
CPI-613
“Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr” NCT03435289 ↗18
“CPI-613® (devimistat) targets the altered energy metabolism and processes for production of ATP and essential bio-intermediates unique to and characteristic of most cancer cell types.” NCT03504410 ↗8
“Devimistat (CPI-613®) is a novel lipoate analog that inhibits the tricarboxcylic acid cycle at two key carbon entry points.” PMID 31512497 ↗Sep 2019
“For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.” NCT05854966 ↗
“Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.” PMID 40674734 ↗Nov 2025
“Devimistat is a TCA cycle inhibitor.” PMID 35354808 ↗Mar 2022
“Inhibition of PDHA1 and OGDH by either shRNA or pharmacological inhibitor by CPI613 dramatically attenuated melanoma progression as well as improved the therapeutic efficacy of...” PMID 37678921 ↗Sep 2023
Modality
Small molecule
“The lipoate derivative CPI-613 is a first-in-class agent that targets mitochondrial metabolism.” PMID 25165100 ↗Aug 2014
“Inhibition of PDHA1 and OGDH by either shRNA or pharmacological inhibitor by CPI613 dramatically attenuated melanoma progression as well as improved the therapeutic efficacy of...” PMID 37678921 ↗Sep 2023
Target
PDHA1
“Inhibition of PDHA1 and OGDH by either shRNA or pharmacological inhibitor by CPI613 dramatically attenuated melanoma progression as well as improved the therapeutic efficacy of...” PMID 37678921 ↗Sep 2023